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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococcus infections are a
worldwide concern. Currently, these isolates have also shown resistance to vancomycin, the last therapy used in these
cases. It has been observed that quinones and other related compounds exhibit antibacterial activity. This study evaluated
the antibacterial activity, toxicity and in vivo dermal irritability of lapachol extracted from Tabebuia avellanedae and
derivatives against methicillin-resistant staphylococcal isolates. In addition, its mechanism of action was also analyzed.
Methods: The compounds β-lapachone, 3-hydroxy β N lapachone and α-lapachone were tested to determine the MIC
values against methicillin-resistant S. aureus, S. epidermidis and S. haemolyticus strains, being the two last ones hetero-
resistant to vancomycin. Experiments of protein synthesis analysis to investigate the naphthoquinones action were
assessed. In vitro toxicity to eukaryotic BSC-40 African Green Monkey Kidney cell cultures and in vivo primary dermal
irritability in healthy rabbits were also performed.
Results: The compounds tested showed antibacterial activity (MICs of 8, 4/8 and 64/128 µg/mL to β-lapachone, 3-
hydroxy β N lapachone and α-lapachone, respectively), but no bactericidal activity was observed (MBC > 512 µg/mL for
all compounds). Although it has been observed toxic effect in eukaryotic cells, the compounds were shown to be atoxic
when applied as topic preparations in healthy rabbits. No inhibition of proteins synthesis was observed.
Conclusion: Our results suggest that quinones could be used in topic preparations against wound infections caused by
staphylococci, after major investigation of the pharmacological properties of the compounds. Studies about the use of
these compounds on tumoral cells could be carried on, due to their effect in eukaryotic cells metabolism.
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Background
The south-american tree Tabebuia avellanedae (Bignon-
eaceae) is known in the popular medicine as Ipê-Roxo, Pau
D'Arco, Lapacho, among others [1,2]. For many decades,
preparations made with this plant were used in South and
North America as antineoplasic, antifungal, antiviral,
antimicrobial, antiparasitical and anti-inflammatory
treatment [1-5]. Pharmacological activities of this species
are related to saponins, flavonoids, coumarins, and natu-
ral antibiotics [3,6], while the chemical profile presented
by most of the studies has shown the quinones as the
main active substances [1-4,6].
The increasing prevalence of multi-resistant bacteria made
the search of new antimicrobial agents an important strat-
egy for the establishment of alternative therapies in diffi-
cult handling infections [3]. Methicillin-resistant
staphylococci infectionsmainly caused by Staphylococcus
aureus (MRSA strains) and by coagulase-negative staphy-
lococci (CNS), as S. epidermidis (MRSE) and S. haemolyti-
cus (MRSH) isolates have increased in the last two decades
[7]. They are the pathogens most frequently isolated from
nosocomial bacteraemias [8], with an attributable mortal-
ity rate ranging from 13% for CNS [9] to 42% for MRSA
[11]. In these cases, the therapy is generally limited to the
use of vancomycin and teicoplanin. However, some Sta-
phylococcus  strains resistant to glycopeptides have been
reported in Brazil [11] and other countries [12]. Then, the
research on new antimicrobial agents is an area of great
importance [5,13].
Several naphthoquinones are found in the nature show-
ing activity against aerobic and anaerobic bacterial spe-
cies. In general, they are active against S. aureus,
Enterococcus faecium and  Bacillus subtilis, but inactive
against Gram-negative bacteria [5]. Its mechanism of
action has not been completely elucidated. The naphtho-
quinone β-lapachone, for example, seems to increase the
generation of superoxide anion and hydrogen peroxide in
Trypanosoma cruzi [14].
In a previous study we described that lapachol derivatives
from Tabebuia avellanedae showed growth inhibitory activ-
ity against MRSA isolates [3]. The aim of the present study
was to evaluate the antimicrobial activity of these drugs
against multi-resistant staphylococci isolates, including
coagulase-negative staphylococcal strains presenting van-
comycin-heterogeneous resistance, and to verify in vitro
toxicity to eukaryotic cell cultures and in vivo primary der-
mal irritability. In addition the mechanism of naphtho-
quinones action was also investigated.
Methods
Bacterial strains
Standard strains of S. aureus ATCC 29213 (Methicillin-
sensible Staphylococcus aureus) and ATCC 33591 (Methi-
cillin-resistant Staphylococcus aureus), and the methicillin-
resistant clinical isolates Staphylococcus epidermidis 228
(MRSE) and Staphylococcus haemolyticus (225) presenting
hetero-resistance to vancomycin and identified in previ-
ous study [15] were used. The clinical strains were isolated
from bloodstream of patients from a tertiary hospital in
Rio de Janeiro city, Brazil. The isolates of S. epidermidis
were characterized as hetero-resistant to vancomycin
through vancomycin agar screening test according to the
National Comittee for Clinical Laboratory Standard
(NCCLS) [16] and by evaluation of the population analy-
sis profile (data not shown). All organisms were plated on
5% sheep blood agar base (Oxoid) at 35°C for 24 h.
Eukaryotic cells
BSC-40 cells from African green monkey kidney were
propagated in Dulbeccos's modified Eagles's medium
(DMEM; Invitrogen) supplemented with 8% calf serum,
2% heat-inactivated bovine serum (BRL/Gibco Laborato-
ries), 50 µg mL-1 gentamicin sulfate, 500 U mL-1 penicillin,
100 µg mL-1 streptomycin, 225 µg/mL sodium bicarbo-
nate and 2,5 µg mL-1 fungizon. Cells were grown as adher-
ent cultures at 37°C in a 5% CO2 incubator [17].
Naphthoquinones
The naphthoquinones derivatives evaluated in this study
(Figure 1) were obtained from the lapachol, which was
Naphthoquinones evaluated in this study Figure 1
Naphthoquinones evaluated in this study. I) Lapachol 
(2-hydroxy-3-(3-methylbut-2-enyl)naphthoquinone); II) α-lapa-
chone (2,2-dimethyl-2H-benzo [g]chromene-5,10-dione); III) β-
lapachone (2,2-dimethyl-3,4-dihydro-2H-benzo [h]chromene-5,6-
dione); IV) (±) 3-hydroxy-β-N-lapachone ((±)3-hydroxy-2,2-
dimethyl-2,3,3a,9b-tetrahydronaphtho [1,2-d] furan-4,5-dione)Annals of Clinical Microbiology and Antimicrobials 2006, 5:5 http://www.ann-clinmicrob.com/content/5/1/5
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isolated by extraction from T. avellanedae sawdust [18].
The reactions were carried out in the laboratory of organic
synthesis of the Natural Products Research Nucleus at
UFRJ (NPPN-UFRJ). The α-lapachone, that we named as
compound I was synthesized according to Hooker [19]
and the other quinones (compounds II, II and IV) were
synthesized according to Pinto and coworkers [20].
Minimal Inhibitory Concentration (MIC) Determination
The MIC was evaluated by the dilution method in Muel-
ler-Hinton broth medium (Oxoid), according to NCCLS
[16], for each one of the naphthoquinones, with concen-
trations ranging from 2 to 512 µg/mL. Bacteria (104 CFU/
mL) were inoculated in the broth with the drug, and incu-
bated at 35°C for 24 h.
Minimal Bactericidal Concentration (MBC) 
Determination
MBC is the smaller concentration of the drug necessary for
elimination of 99.9% of the microorganisms tested. The
MBC was determined after the MIC assays. Tubes where
the MIC results showed no bacterial growth, an aliquot of
0.1 mL was seeded in Mueller-Hinton agar without addi-
tion of drugs and the bacterial growth was evaluated for
the MBC determination. After 24 h, at 35°C, if MIC =
MBC or if MBC is one, two or three dilutions above of
MIC, the drug is considered bactericide [21].
Protein synthesis analysis by SDS-PAGE
An overnight culture of S. aureus ATCC 33591 was diluted
in BHI to 107 CFU/mL and incubated for 30 min at 37°C.
For labeling, cells were concentrated to 108 CFU/mL in a
methionine-free medium (MEM, Gibco) containing 200
µCi/mL of [35S] methionine (Amershan) and subject to
drug addition, compound IV or menadione (vitamin K3)
[22] at final concentrations of 8, 16 and 32 µg/mL at
37°C, or heat treatment at 45°C [23]. In all the tests, the
cells were pulse-labeled for 30 minutes and collected by
centrifugation at 12,000 g for 5 min. The cells were lysated
with the addition of 40 ng/mL of lysostaphin (S. aureus)
during 2 hours at 37°C. After incubation period, equal
volumes of 0.5 M Tris-HCl (pH 7.2) buffer containing 4%
SDS, 10% β-mercaptoethanol, 20% glycerol and 0.1 %
bromophenol blue were added, and the samples were
boiled for 5 min. Cellular extracts were subjected to Poly-
acrylamide Gel Electrophoresis (SDS-PAGE) analysis. The
gel was stained with Comassie-blue, destained, dried and
exposed to X-ray films.
Cell viability by Neutral Red test
The neutral red assay is based on the incorporation of the
supravital dye neutral red into living cells. Confluent
monolayers of BSC-40 cells (96-well plate) were incu-
bated with a specified concentration of the naphthoqui-
nones for 24 h at 37°C. The control was performed in
absence of drugs. Neutral red stock solution (0.1%) was
prepared in deionized water and stored at room tempera-
ture. Before staining, a fresh 1:100 dilution of the dye was
prepared. In accordance to Thompson (1998) [17], 100
µl/well of medium containing neutral red were added to
living cells (50 µg/ml final concentration), and the micro-
plates were incubated at 37°C in moist atmosphere with
5% CO2 for 3 h. The cells were then washed with 4% for-
maldehyde and incubated at room temperature for 1 min.
After formaldehyde discarding, methanol solution (50%)
was added and incubated at room temperature for 20
min. The optical density at 490 nm was measured using a
microtiter plate spectrophotometer. The uptake of neutral
red is proportional to the number of viable (live) cells
[21].
Primary dermal irritability test
This test was performed according to Draize (1944) [24].
Different concentrations of the naphthoquinones were
prepared, according to Table 1. Ten healthy rabbits were
selected for each drug solution and the animals separated
for chamber adaptation 48 hours before the assay. The
animals had not alimentary restrictions and periods of
dark and light were intercalated in each 12 hours. The
ambient temperature was maintained at 25 ± 2°C. The
animals were depilated on the dorsal region 24 hours
before the assay. The dorsal region was divided in two
parts: the right side, with two limited areas with no blood-
ing chases, and the left one, with two limited areas with
Table 1: Antimicrobial activity of naphthoquinones against Staphylococcus species.
Compounds S. aureus ATCC 29213 (MSSA) S. aureus ATCC 33591 
(MRSA)
S. epidermidis MRSE 228 S. haemolyticus MRSH 225
MIC (µg/mL) MBC (µg/mL) MIC (µg/mL) MBC (µg/mL) MIC (µg/mL) MBC (µg/mL) MIC (µg/mL) MBC (µg/mL)
Ia 2 5 6 > 5 1 2 2 5 6 > 5 1 2 N DN DN DN D
II 64 >512 64 >512 128 >512 128 >512
I I I 8> 5 1 28> 5 1 28> 5 1 28> 5 1 2
I V 8> 5 1 28> 5 1 24> 5 1 28> 5 1 2
ND → not determined. Compounds: I) Lapachol; II) α-lapachone; III) β-lapachone; IV) (±) 3-hydroxy-β-N-lapachone. MIC = Minimal Inhibitory 
Concentration MBC = Minimal Bactericidal ConcentrationAnnals of Clinical Microbiology and Antimicrobials 2006, 5:5 http://www.ann-clinmicrob.com/content/5/1/5
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intact skin. The concentrations of the alcoholic solutions
of the naphthoquinones related to the MIC obtained
(Table I) were applied on the pre-established limited areas
of the animals. The compound IV was also tested in the
concentration of 0.8 mg/mL (MIC 100×). The rabbits
were in contact with the solution of the naphthoquinones
during four hours, and observations were done during 24,
48, 72 and 96 hours. During this period, the appearance
of inflammatory reactions (edema and/or erythematic
areas) or any other toxic reactions due to the substances
was evaluated. The signals and symptoms observed were
classified in agreement with the Federal Hazardous Sub-
stances Act of the United States.
Results
MIC and MBC determination
The MIC and MBC determination was performed to com-
pare the antimicrobial effect of the naphthoquinones in
MSSA and MRSA strains (S. aureus) and evaluate this effect
in resistant coagulase-negative staphylococci (S. epider-
midis and S. haemolyticus). The antimicrobial activity of
the compounds against S. aureus (ATCC 29213 and ATCC
33591),  S. epidermidis MRSE 228 and S. haemolyticus
MRSH 225 isolates are shown in the Table 1. Compounds
III and IV showed the best results, inhibiting the growth of
all bacteria at concentration of 8 µg/mL. For the isolate S.
epidermidis, the compound IV showed a MIC of 4 µg/mL.
A MBC above 512 µg/mL was seen for all the compounds
tested, indicating an antibacteriostatic activity.
Protein synthesis analysis
To investigate a possible mechanism of action of naph-
thoquinones on the bacteria protein synthesis, the com-
pound IV were selected to perform this analyze since it
presented the lowest MIC. So, (±) 3-hydroxy-β-N-lapa-
chone (compound IV) were added to the staphylococcal
cells at different concentrations (8, 16 and 32 µg/mL) in
the presence of 35S-Met as described in Materials and
Methods. After SDS-PAGE, the corresponding autoradio-
gram showed that this compound did not inhibit the bac-
terial protein synthesis at the tested concentrations but
induced the expression of some proteins of 100, 70, 60
and 10 KDa (Figure 2). The same pattern of induction was
observed when cells were submitted to 45°C. We have
previously identified these proteins as heat-shock proteins
(HSPs) also known as stress proteins [23]. In order to
determine if the cellular stress caused by the compound IV
could be related to oxidative stress, the menadione (vita-
min K3) [22], a well known oxidative stress agent, was
tested at 8, 16 e 32 µg/mL, showing the same pattern of
induction (data not shown). These results showed that the
naphthoquinones analyzed cause a stress reaction in bac-
terial cell, suggesting that it could be related to oxidative
stress.
Cytotoxicity
The cytotoxicity was evaluated to determine the toxic con-
centration of these compounds and compare with the
antibacterial concentration observed (MIC), for further
analysis of their application in antimicrobial therapy. The
compounds presented a considerable cytotoxicity. A con-
centration of 2 µg/mL of the compound IV was sufficient
to kill 80% of the cell culture, while its minimal concen-
tration to inhibit the bacteria was 8 µg/mL. It was
observed that the other compounds are less toxic than
compound IV. The precursor (compound I) did not
present a severe toxicity to BSC-40 cells when compared to
the other compounds used at the same concentration
(Figure 3). The minimal inhibitory concentrations of the
other substances tested with eukaryotic cells are listed in
the Table 2. This effect on BSC-40 cells suggests that these
compounds could be used in antineoplasic therapy or
antibacterial therapy as topic preparations.
Primary dermal irritability test
This assay was performed to determine the toxicity of
these compounds (previously considerable a toxic sub-
stance after the cytotoxicity determination) in topic prep-
arations. No damage was observed on the limited dermal
areas of the animals evaluated at the periods of 24, 48, 72
and 96 hours after the application of naphthoquinones
solutions in all concentrations used, including a concen-
Analysis of proteins synthesis Figure 2
Analysis of proteins synthesis. Autoradiogram of a SDS-
PAGE protein profile of the S. aureus strain ATCC 29213 
labeled in the presence of [35S] Met (200 µCi/mL) for 30 min 
at 37°C (lane 1) or at three concentrations of compound IV 
(±) 3-hydroxy-β-N-lapachone (8, 16 and 32 µg/mL – lanes 2, 
3 and 4). The arrows on the right indicate the induced pro-
teins and their molecular weight in kDa.Annals of Clinical Microbiology and Antimicrobials 2006, 5:5 http://www.ann-clinmicrob.com/content/5/1/5
Page 5 of 7
(page number not for citation purposes)
tration 100× higher than the MIC found for the com-
pound IV (Table 3). Then, these compounds did not show
dermal irritability when used in topic preparations.
Discussion
The search for new antimicrobial agents is of great con-
cern today, because of the multiple drugs resistance
acquired by several pathogens [7]. Currently, in Latin
America, the methicillin resistance rates are higher than
40% among S. aureus isolates and they are above 70 %
among CNS isolates [8]. These strains present the mecA
gene that encodes a low antibiotic-affinity penicillin-
binding protein [7]. Normally, these multi-drug resistant
strains are susceptible only to vancomycin [12]. However,
the large use of this antimicrobial in hospitals has favored
the emergence of vancomycin resistant species, including
S. aureus [12],  S. epidermidis and  S. haemolyticus [11].
Then, the research of new drugs is interesting.
In this study, bacterial growth inhibition by naphthoqui-
nones showed that the synthetic compounds II (α-lapa-
chone), III (β-lapachone) and IV [(±) 3-hydroxy-β-N-
lapachone] were more effective than their precursor lapa-
chol (compound I), mainly the compounds III and IV.
Structural analysis of the compound IV shows that its
higher toxic and antimicrobial action could be associated
with a hydroxyl group (OH) inserted at furan ring (Fig. 1),
as well as related to the naphtho 1,2-quinoidal system
that is present in both compounds III and IV, making
them more effective than the other compounds tested
against the MRSA, MRSE and MRSH isolates. The results
show that these naphthoquinones have considerable
activity against staphylococci (MICs from 4 to 128 µg/
mL), as we have previously reported [3], although the
activity presented by the compounds has been bacterio-
static (MBCs > 512 µg/mL). Naphthoquinones activity
was observed even against vancomycin hetero-resistant
isolates, suggesting that they could be an alternative anti-
microbial agent in therapeutic of multi-resistant staphylo-
coccal infections.
Bacterial protein synthesis was not inhibited by naphtho-
quinones, as it was demonstrated by SDS-PAGE analysis.
However, it was observed that some proteins of molecular
weight of 100, 70, 60 and 10 KDa, referred as stress pro-
teins, had their levels increased by heat [23] and by mena-
dione treatment [22]. As these proteins are associated with
bacterial stress, naphthoquinones could have induced an
oxidative stress in all microorganisms, since this class of
substance is involved with cell toxicity. It is supposed that
these substances promote an oxidative stress in the mem-
brane of the bacterial cell when ATP synthesis occurs in
the respiratory chain [25]. Quinones are coenzyme Q ana-
logs (ubiquinone, an electron-transfer substance that car-
ries out the electrons of reduced NAD of the complex I to
III), competing with these substances. When the respira-
tory chain is affected, several reactive-radicals like hydro-
gen peroxide, hydroxyl radical and superoxide anion have
an increase in their concentrations, causing an oxidative
stress [25,26]. So, the results here presented show that the
naphthoquinones analyzed cause a stress reaction in bac-
terial cell and suggest that it could be related to oxidative
stress.
When the compounds were tested in eukaryotic cells
(BSC-40), a cytotoxic effect was observed. The data in
Table 2 shows that the toxic concentration of all com-
pounds to the eukaryotic cells corresponded to a quarter
of their MIC values. These results show that these sub-
stances cannot be used by endogenous administration
Table 2: Comparative activity of the compounds against bacterial and eukaryotic cells
Compound Minimal Inhibitory Concentrationa (µg/mL) Minimal Toxic Concentrationb (µg/mL)
I2 5 6 > 1 6
II 64 16
III 8 2
IV 8 2
Compounds: I) Lapachol; II) α-lapachone; III) β-lapachone; IV) (±) 3-hydroxy-β-N-lapachone
a MIC – assayed with MRSA strain (ATCC 33591); b assayed on BSC-40 cells
Table 3: Concentrations of the naphthoquinones used in dermal irritability test
Compound MIC 100× MIC
I 0.03 % (256 µg/mL) ND
II 0.01 % (64 µg/mL) ND
III 0.001% (8 µg/mL) ND
IV 0.001% (8 µg/mL) 0.1 % (800 µg/mL)
N.D. → not determined. MIC = Minimal Inhibitory Concentration. Compounds: I) Lapachol; II) α-lapachone; III) β-lapachone; IV) (±) 3-hydroxy-β-
N-lapachone.Annals of Clinical Microbiology and Antimicrobials 2006, 5:5 http://www.ann-clinmicrob.com/content/5/1/5
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once they could lead to damage to human cells. However,
when the substances were applied as a topic preparation
in rabbits, no damage was observed, even when it was
used at high concentrations, as seen for the compound IV
tested in a concentration 100× higher (800 µg/mL) than
the MIC observed for it. These results show that it would
be possible to propose a topic use for this compound,
either in prophylactic procedures or in the treatment of
wound infections after major investigation in relation to a
long term application on the derm and blood levels of the
compounds.
Some authors describe naphthoquinones with a large
antitumoral activity [2,27]. In this study, although the
compounds had presented a high toxic concentration in
normal epithelial cells, a therapy with these substances
would be possible once the tumor cells have a large meta-
bolic rate. Naphthoquinones would be metabolized
firstly by neoplasic cells, acting like other toxic chemo-
therapeutic agents as base analogs, alquilants, and others
used in the antitumoral therapy [2,27].
In this study a relationship between structure and toxicity
of the different naphthoquinones was observed. Table 2
shows that the substances with lower MIC (4 – 8 µg/mL)
presented the highest toxicity (compounds III and IV),
while the compound I with a higher MIC (256 µg/mL) did
not show any toxic effect at the tested concentrations. It
can be considered that structural modifications had a pro-
nounced effect in the activity of the substances. Further
studies involving structural modifications will be neces-
sary to decrease their toxicity to eukaryotic cells, maintain-
ing or increasing the antibacterial activity.
Conclusion
In conclusion, naphthoquinones are an interesting class
of natural compounds with antibacterial activity, and
could be used mainly as topical drugs against staphyloco-
ccal infections, after major investigation of the pharmaco-
logical properties of the compounds However, due to the
cell toxicity shown for many representatives of them,
structural modifications can be an important strategy to
produce new molecules, less toxic, to be used on tumor
cells, due to the fact these substances present a large effect
in eukaryotic cells metabolism.
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